NO20020605L - Use of CGRP antagonists and CGRP release inhibitors for combating menopause heatstroke - Google Patents

Use of CGRP antagonists and CGRP release inhibitors for combating menopause heatstroke

Info

Publication number
NO20020605L
NO20020605L NO20020605A NO20020605A NO20020605L NO 20020605 L NO20020605 L NO 20020605L NO 20020605 A NO20020605 A NO 20020605A NO 20020605 A NO20020605 A NO 20020605A NO 20020605 L NO20020605 L NO 20020605L
Authority
NO
Norway
Prior art keywords
cgrp
heatstroke
menopause
combating
release inhibitors
Prior art date
Application number
NO20020605A
Other languages
Norwegian (no)
Other versions
NO20020605D0 (en
Inventor
Henri Doods
Wolfgang Eberlein
Wolfhard Engel
Klaus Rudolf
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20020605L publication Critical patent/NO20020605L/en
Publication of NO20020605D0 publication Critical patent/NO20020605D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
NO20020605A 1999-08-10 2002-02-07 Use of CGRP antagonists and CGRP release inhibitors for combating menopause heatstroke NO20020605D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19937304A DE19937304C2 (en) 1999-08-10 1999-08-10 Use of CGRP antagonists to combat menopausal hot flashes
PCT/EP2000/007613 WO2001010425A2 (en) 1999-08-10 2000-08-05 Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes

Publications (2)

Publication Number Publication Date
NO20020605L true NO20020605L (en) 2002-02-07
NO20020605D0 NO20020605D0 (en) 2002-02-07

Family

ID=7917551

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020605A NO20020605D0 (en) 1999-08-10 2002-02-07 Use of CGRP antagonists and CGRP release inhibitors for combating menopause heatstroke

Country Status (32)

Country Link
EP (1) EP1207884B1 (en)
JP (1) JP2003506403A (en)
KR (1) KR100713573B1 (en)
CN (1) CN1166361C (en)
AR (1) AR025078A1 (en)
AT (1) ATE281168T1 (en)
AU (1) AU777709B2 (en)
BG (1) BG65366B1 (en)
BR (1) BR0013009A (en)
CA (1) CA2378428C (en)
CZ (1) CZ300513B6 (en)
DE (2) DE19937304C2 (en)
EA (1) EA007531B1 (en)
EE (1) EE04928B1 (en)
ES (1) ES2231243T3 (en)
HK (1) HK1046854B (en)
HR (1) HRP20020117A2 (en)
HU (1) HUP0202397A3 (en)
IL (1) IL148057A (en)
MX (1) MXPA02001373A (en)
MY (1) MY129668A (en)
NO (1) NO20020605D0 (en)
NZ (1) NZ517367A (en)
PL (1) PL198483B1 (en)
PT (1) PT1207884E (en)
SK (1) SK285587B6 (en)
TR (1) TR200200359T2 (en)
TW (1) TWI285550B (en)
UA (1) UA73137C2 (en)
WO (1) WO2001010425A2 (en)
YU (1) YU8302A (en)
ZA (1) ZA200200997B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19952147A1 (en) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma New cyclopropanes, pharmaceutical compositions containing these compounds and process for their preparation
DE10139410A1 (en) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Use of BIBN4096 in combination with other anti-migraine drugs for the treatment of migraines
AU2002359458A1 (en) 2001-12-12 2003-06-23 Eli Lilly And Company Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10206770A1 (en) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma New, stable acid addition salts of the quinazolinone derivative CGRP antagonist BIBN4096, useful for the treatment of migraine, in the form of an inhalable powder
DE10207026A1 (en) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Stable inhalable powder of the calcitonin gene-related peptide antagonist, BIBN4096, useful for treating migraine, in the form of spherical nano-structured particles obtained by spray-drying
DE10227294A1 (en) * 2002-06-19 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Preparations for intranasal application of selected amino acid-derived CGRP antagonists and processes for their preparation
DE10250080A1 (en) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10300973A1 (en) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg New carboxylic acids and their esters, medicaments containing these compounds and processes for their preparation
CA2531407A1 (en) * 2003-07-07 2005-01-20 Boehringer Ingelheim International Gmbh Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients
CN100418948C (en) * 2003-07-15 2008-09-17 麦克公司 Hydroxypyridine cgrp receptor antagonists
DE10338399A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Microparticles containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine, process for their preparation and their use as inhalation powder
DE102004015723A1 (en) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
US7696195B2 (en) 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004019492A1 (en) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
DE102004063752A1 (en) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of selected CGRP antagonists to combat menopausal hot flashes
DE102004063755A1 (en) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of CGRP antagonists for the treatment and prevention of hot flushes in patients with prostate cancer
EP1770091A1 (en) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-antagonists, process for their preparation as well as their use as medicaments
US7491717B2 (en) 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7439237B2 (en) 2005-04-15 2008-10-21 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009056A1 (en) * 1995-09-07 1997-03-13 L'oreal Extract of iridaceae and compositions containing such extract
US5910482A (en) 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US5710024A (en) * 1996-07-23 1998-01-20 Smithkline Beecham Corporation Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
SK285631B6 (en) * 1996-09-10 2007-05-03 Dr. Karl Thomae Gmbh Modified amino acids, pharmaceutical composition comprising its and its use
DE19911039A1 (en) * 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Modified amino acid amides, pharmaceutical compositions containing these compounds and process for their preparation

Also Published As

Publication number Publication date
ES2231243T3 (en) 2005-05-16
AU6992800A (en) 2001-03-05
CN1370069A (en) 2002-09-18
HK1046854A1 (en) 2003-01-30
HK1046854B (en) 2005-02-25
BR0013009A (en) 2002-04-30
BG106391A (en) 2002-09-30
ATE281168T1 (en) 2004-11-15
PT1207884E (en) 2004-12-31
KR20020016947A (en) 2002-03-06
MXPA02001373A (en) 2002-07-30
HUP0202397A3 (en) 2006-07-28
BG65366B1 (en) 2008-04-30
DE19937304A1 (en) 2001-03-15
IL148057A (en) 2008-04-13
PL198483B1 (en) 2008-06-30
UA73137C2 (en) 2005-06-15
YU8302A (en) 2004-12-31
SK285587B6 (en) 2007-04-05
IL148057A0 (en) 2002-09-12
EE04928B1 (en) 2007-12-17
KR100713573B1 (en) 2007-05-02
WO2001010425A2 (en) 2001-02-15
HRP20020117A2 (en) 2003-10-31
CZ300513B6 (en) 2009-06-03
TWI285550B (en) 2007-08-21
EA007531B1 (en) 2006-10-27
DE50008527D1 (en) 2004-12-09
EA200200207A1 (en) 2002-08-29
EE200200061A (en) 2003-04-15
CA2378428A1 (en) 2001-02-15
SK1972002A3 (en) 2002-06-04
CZ2002497A3 (en) 2002-06-12
NZ517367A (en) 2004-09-24
DE19937304C2 (en) 2003-08-21
MY129668A (en) 2007-04-30
AR025078A1 (en) 2002-11-06
TR200200359T2 (en) 2002-05-21
PL364049A1 (en) 2004-12-13
EP1207884A2 (en) 2002-05-29
CA2378428C (en) 2009-10-20
AU777709B2 (en) 2004-10-28
ZA200200997B (en) 2002-10-30
EP1207884B1 (en) 2004-11-03
CN1166361C (en) 2004-09-15
HUP0202397A2 (en) 2002-10-28
JP2003506403A (en) 2003-02-18
WO2001010425A3 (en) 2002-02-07
NO20020605D0 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
NO20020605D0 (en) Use of CGRP antagonists and CGRP release inhibitors for combating menopause heatstroke
NO20023729D0 (en) Controlled release preparations containing opioid agonist and antagonist
ATE253576T1 (en) 8-QUINOLINXANTHINE AND 8-ISOCHINOLINXANTHINE DERIVATIVES AS PDE 5 INHIBITORS
DE60020100D1 (en) DIMERBINDUNGEN AND AS INHIBITORS OF NEURAMIDINASE
ATE432264T1 (en) CYCLOALKYL-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS PARP INHIBITORS
DE59908600D1 (en) SUBSTITUTED BENZIMIDAZOLE AND THEIR USE AS PARP INHIBITORS
EE05585B1 (en) Indazole compounds and pharmaceutical compositions for the inhibition of protein kinases and their use
CY2008010I1 (en) COMPOUNDS INCLUDING DIPEPTYDYLOPEPTIDASE-IV INHIBITORS AND ANTI-DIABETIC AGENTS
DE60132799D1 (en) PEROXISOM PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS
NO20021329L (en) Kinase inhibitors as therapeutic agents
IL146080A0 (en) Use of pde inhibitors for improved fecundity in mammals
NO20032270D0 (en) Imidazole and benzimidazole caspase inhibitors and their use
PT1237559E (en) PHARMACEUTICAL COMBINATIONS COMPREHENDING AN ANTAGONIST OF THE P2T AND MEGALATRAN RECEPTOR
EE200400042A (en) 8/17 Heterocyclic Compounds and Their Use as D-Alanyl-D-Alanine Ligase Inhibitors
EE200100611A (en) New pharmaceutical combinations of NOS inhibitors
DK1131083T3 (en) Use of growth hormone releasing compounds and antagonists thereof for the treatment of tumors
IS2536B (en) PDE4 or PDE3 / 4 inhibitor and histamine receptor antagonist preparations
HUP0500078A3 (en) Pharmaceutical composition containing a combination of a pde inhibitor and a leukotriene receptor antagonist
PL369736A1 (en) New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
HU0001888D0 (en) 5ht1 receptor agonists and either cox-2 inhibitor or nsaid for the treatment of migraine
ID28227A (en) USE OF NEW PHARMACEUTICALS FOR NOS INHIBITORS
IL136961A0 (en) 5ht1 receptor agonists, caffeine and either a cox-2 inhibitor or nsaid for the treatment of migraine
HUP0001889A3 (en) Pharmaceutical compositions containing 5ht1 receptor agonists and a cox-2 inhibitor for treating migraine
NO20014590D0 (en) Use for the protection of young needles
EE200300075A (en) A pharmaceutical combination of angiotensin II antagonists and ACE inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application